Board of Directors

Dr. Armin Spura became a Strategic Advisor and Board Observer to SeromYx in Oct 2021 and was elected to the Board in 2022. Dr. Spura is currently Chief Executive Officer at global CRDMO BioDuro. He joined BioDuro from Crown Bioscience, where he served as the Chief Executive Officer (CEO) for nearly five years, guiding the company through significant growth and strategic development. Throughout his career, Armin has held senior leadership positions at well-known organizations such as Thermo Fisher Scientific, WuXi NEXTCODE, CareDx and Ion Torrent. Early in his career, Armin helped to grow two startup companies, Ingenuity Systems (acquired by Qiagen) and ForteBio (now part of Danaher). Armin studied biochemistry in Germany and received his Doctor of Philosophy (PhD) in molecular biology from Brown University.

Ken Kelley has over 35 years of entrepreneurial, venture capital, operational and technical biotechnology experience. He currently serves on the Board of Directors of Adjuvance Technologies, ID Biologics, Meissa Vaccines, Public Health Vaccines, and publicly held Halozyme Therapeutics. Previously, Mr. Kelley was co-founder, CEO and Chairman of PaxVax. Mr. Kelley was a venture capitalist at K2 BioVentures, Latterell Venture Partners and Institutional Venture Partners (IVP) and has made over 40 biotechnology and medical startup investments. Mr. Kelley was a White House Presidential Executive Fellow from 2016-2017 as well as an Advanced Leadership Initiative (ALI) Fellow at Harvard University from 2015-2016. He earned an M.B.A. from Stanford University and a B.A. in Biochemical Sciences from Harvard University.

Lorraine Marchand is a highly accomplished and solutions-driven life sciences product development and commercialization executive with multifaceted experience in P&L management, mergers and acquisitions, operations management, clinical development, product launch, and strategic planning. She has a proven track record of success in leading capabilities and solution development, go-to-market strategy, business development, customer relationships, sales, and delivery. Lorraine leverages exemplary leadership, organizational, and communication skills to execute business strategies that accelerate top-line and bottom-line growth, deliver outstanding results, and maximize a company’s commercial success. She has held leadership positions at Bristol Myers Squibb, IBM, LabCorp/Covance, Cognizant, and IQVIA, and has cofounded four companies. Marchand is an adjunct professor of management and serves on the Healthcare and Pharmaceutical Management Program Advisory Board at Columbia Business School and is an adjunct professor of innovation and entrepreneurship at Yeshiva University’s Katz School of Science and Health. She is also an investor-member of venture firm Plum Alley and a mentor to two startup accelerators.

Piers Whitehead, co-founder and former CEO, has over 20 years of experience in the biopharma industry with a focus on commercial and business development functions in the fields of vaccines, immunology and public health.  Over his career to date, he has led partnering transactions that generated over $450m in cash, played a key role in an IPO, led a complex acquisition and integration, led a multi-national, multi-product commercial function, co-authored US government grants and contracts with a headline value of greater than $1bn and executed multiple in-licenses from academia, the US Government and private companies.  As Chief Business Officer of PaxVax, he led a successful process to sell a Priority Review Voucher; in-licensed the IP for the Company’s second commercial product; and designed and executed the acquisition and integration of vaccine assets from J&J/Crucell. Mr Whitehead holds a BA with honours from Oxford University.

Andrew Ball brings over 20 years of global leadership experience and value creation in the life sciences industry, with a successful track record in technological and commercial development of assay platforms and services, spanning startups to large multinationals. Prior to joining SeromYx in 2025, he served as Vice President, Assay Development Platforms at Abcam, a Danaher company, where he led a global R&D organization developing and commercializing immunoassays, cell-based assays, antibody conjugates, recombinant proteins and contract assay services.  He has also held roles as VP of Assay Development at Quanterix, developing ultrasensitive assays for neurodegenerative disease and immuno-oncology; as VP of R&D at Quad Technologies, a cell and gene therapy startup acquired by Bio-Techne, and has served in a variety of innovation and strategic leadership roles at MilliporeSigma. He studied at Ulster University and held post-doctoral positions at Louisiana State University and the Sanford-Burnham Medical Institute.